Use of an In Vivo Optical Probe to Discriminate Benign From Malignant Thyroid Nodules
NCT01401855 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2016-06-17
Summary
This study will investigate the usefulness of an optical probe in the differentiation of thyroid cancer from normal thyroid tissue in a thyroidectomy specimen. This is the next step in the research that this team has conducted through our prior Institutional Review Board (IRB)H-28135, in which the investigators successfully demonstrated that use of the optical probe readings on thyroid specimens ex vivo could successfully discriminate benign from malignant disease. The Elastic Scattering Spectroscopy (ESS) probe has also been IRB approved and a clinical trial conducted in vivo at Boston University/Boston Medical Center by Dr. Satish Singh and Dr. Irving Bigio. The investigators intend to now bring this project to the clinical setting of thyroid disease. The optical real-time readings will be compared to the histological analysis from the same area. Subjects already undergoing thyroid biopsy for thyroid disease including thyroid nodules, thyroid cancer and thyroid goiter with nodules will be eligible to participate. During the already scheduled thyroid procedure using a fine needle aspiration biopsy needle, optical readings will be taken from the thyroid gland and these same areas will then be analyzed in the usual standard fashion. The reading will then be correlated with the histological results. In addition, if lymph nodes are biopsied as part of the evaluation they will also be tested prior to histological standard processing. All specimens and data will be de-identified once data collection and analysis is complete. Our goal is to use optical real-time readings to improve the differential diagnosis of benign from malignant thyroid nodules and avoid surgery for the purpose of diagnosis alone.
Conditions
- Cancer
- Thyroid
Sponsors & Collaborators
-
Fraunhofer USA
collaborator UNKNOWN -
Boston Medical Center
lead OTHER
Principal Investigators
-
Jennifer Rosen, MD/FACS · Boston University
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-06-30
- Primary Completion
- 2014-06-30
- Completion
- 2014-06-30
Countries
- United States
Study Locations
More Related Trials
-
HRQOL in Thyroid Cancer and Thyroid Tumours
NCT03676348 ·Status: RECRUITING
-
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
NCT04948437 ·Status: ACTIVE_NOT_RECRUITING
-
A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours
NCT01736163 ·Status: COMPLETED
-
Tri-modal Imaging Instrument for Thyroid Cancer
NCT02758158 ·Status: COMPLETED ·Phase: NA
-
Circulating Biomarkers to Identify Thyroid Cancer
NCT04594720 ·Status: COMPLETED
-
The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma
NCT06268600 ·Status: RECRUITING ·Phase: NA
-
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
NCT05733013 ·Status: RECRUITING
-
I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer
NCT01704586 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition
NCT04619316 ·Status: UNKNOWN ·Phase: PHASE2
-
Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma
NCT01149161 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
OnT4-Thyroglobulin Assay Before rhTSH-Aided Radioiodine Ablation
NCT00439127 ·Status: COMPLETED
-
Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?
NCT01837745 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Hyperthyroid Follow-Up Study
NCT02989103 ·Status: COMPLETED
-
The Role of Midkine in Diagnosis of Thyroid Cancer
NCT03978351 ·Status: UNKNOWN
-
Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy.
NCT04281875 ·Status: COMPLETED ·Phase: NA
-
Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine.
NCT06134830 ·Status: NOT_YET_RECRUITING
-
Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients
NCT00435851 ·Status: UNKNOWN ·Phase: PHASE3
-
Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules
NCT00316823 ·Status: COMPLETED ·Phase: NA
-
Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules.
NCT02953288 ·Status: UNKNOWN
-
Near-infrared Fluorescence With Indocyanine Green for Identification of Sentinels and Parathyroids During Thyroidectomy
NCT04424485 ·Status: UNKNOWN ·Phase: NA
-
Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up
NCT04290663 ·Status: RECRUITING ·Phase: PHASE3
-
Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration
NCT00196729 ·Status: COMPLETED ·Phase: PHASE3
-
Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)
NCT02156362 ·Status: UNKNOWN ·Phase: NA
-
"Clinical Evaluation of Opto-Acoustic Tomography for Detection and Diagnostic Differentiation of Thyroid Nodules"
NCT03032198 ·Status: TERMINATED ·Phase: NA
-
Biosignals by Wearable Devices in Hypothyroidism
NCT04332770 ·Status: COMPLETED